Form 4 DANAHER CORP /DE/ For: Jul 15 Filed by: Couchara Georgeann
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
KeyBanc Remains Positive on Life Sciences as 'Strong' Earning Season Begins with Danaher (DHR) Report
July 21, 2022 11:40 AM EDTKeyBanc analyst Paul Knight comments "Bioprocess market leaders Sartorius (SRT3) and Danaher (DHR) published 2Q22 results this morning with strong revenue and EPS beats, providing a positive backdrop for the industry at large. Results clearly indicate bioprocess companies are witnessing high-levels of demand, making up for the headwinds posed... More
UBS on Danaher (DHR): 'we believe the CPHD platform will continue to see traction as COVID-19 becomes endemic'
July 21, 2022 11:24 AM EDTUBS analyst Elizabeth Garcia reiterated a Buy rating and $297.00 price target on Danaher (NYSE: DHR).
The analyst comments "DHR kicked off 2Q22 life sciences tools earnings and reported a 2Q beat driven by the base business (+8% vs. +MSD% guidance) and COVID (+1.5% vs. -LSD... More
Stifel Reiterates Hold Rating on Danaher (DHR), 'we are impressed with the company's ability to perform'
July 21, 2022 10:21 AM EDTStifel analyst Daniel Arias reiterated a Hold rating and {REMOVEPT} price target on Danaher (NYSE: DHR).
The analyst comments "Danaher reported 2Q22 revenues of $7.75B (+7.5% y/y), which was above Stifel ($7.12B) and consensus ($7.31B). Core revenue growth of 9.5% was ahead of expectations on... More
